Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 7/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 5/20 | 1.00 |
| ▸ | PDE1A | P54750 | 3/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 3/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 3/20 | 1.00 |
| ▸ | PDE11A | Q9HCR9 | 3/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 2/20 | 0.65 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582862 | 1.00 | MET (1.00) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL29583320 | 1.00 | MET (1.00) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL2697990 | 1.00 | MET (1.00) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL9910509 | 1.00 | MET (1.00) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL4197071 | 1.00 | MET (1.00) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL14345665 | 0.88 | MET (0.78) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL2699300 | 0.86 | MET (1.00) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL2696561 | 0.86 | MET (1.00) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL2697942 | 0.86 | MET (1.00) | METPDE3APDE3BPDE1APDE4C | |
| SCHEMBL1659791 | 0.86 | MET (0.75) | METPDE3APDE3BPDE1APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4483875-A2 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3454862-B1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023069888-A1 | ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF | Tavotek Biotherapeutics (Hong Kong) Limited (CN) | 2023-04-27 | — | — | WO | disclosed |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-8212041-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2008008539-A2 | FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | AMGEN INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE3B 1730/4885 |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE3B 1730/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | MET 753/4885PDE3A 4871/4885PDE3B 4866/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE3B 1730/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | MET 163/4885PDE3A 4878/4885PDE3B 4875/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | MET 277/4885PDE3A 4571/4885PDE3B 4696/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MET 301/4885PDE3A 4622/4885PDE3B 4713/4885 |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MET 399/4885PDE3A 4495/4885PDE3B 4669/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | MET 796/4885PDE3A 4623/4885PDE3B 4762/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE3B 1730/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885PDE3A 1765/4885PDE3B 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.